Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Nicholas C, Tutt, Andrew NJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053124/
https://www.ncbi.nlm.nih.gov/pubmed/23146216
http://dx.doi.org/10.1186/bcr3332
_version_ 1782320326084919296
author Turner, Nicholas C
Tutt, Andrew NJ
author_facet Turner, Nicholas C
Tutt, Andrew NJ
author_sort Turner, Nicholas C
collection PubMed
description A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed.
format Online
Article
Text
id pubmed-4053124
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40531242014-06-12 Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Turner, Nicholas C Tutt, Andrew NJ Breast Cancer Res Editorial A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed. BioMed Central 2012 2012-11-13 /pmc/articles/PMC4053124/ /pubmed/23146216 http://dx.doi.org/10.1186/bcr3332 Text en Copyright © 2012 BioMed Central Ltd
spellingShingle Editorial
Turner, Nicholas C
Tutt, Andrew NJ
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
title Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
title_full Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
title_fullStr Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
title_full_unstemmed Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
title_short Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
title_sort platinum chemotherapy for brca1-related breast cancer: do we need more evidence?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053124/
https://www.ncbi.nlm.nih.gov/pubmed/23146216
http://dx.doi.org/10.1186/bcr3332
work_keys_str_mv AT turnernicholasc platinumchemotherapyforbrca1relatedbreastcancerdoweneedmoreevidence
AT tuttandrewnj platinumchemotherapyforbrca1relatedbreastcancerdoweneedmoreevidence

Ejemplares similares